Vanguard Group Inc Mei Pharma, Inc. Transaction History

Vanguard Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	BUY	$0.22 - $8.4 $509 - $19,454	2,316 Added 0.03%	7,671,024 $1.84 Million
Q3 2022 Nov 14, 2022	BUY	$0.41 - $8.8 $132,417 - $2.84 Million	322,969 Added 4.4%	7,668,708 $2.97 Million
Q2 2022 Aug 12, 2022	BUY	$0.42 - $0.65 $461,894 - $714,836	1,099,749 Added 17.61%	7,345,739 $4.44 Million
Q1 2022 May 13, 2022	BUY	$0.54 - $2.74 $257,175 - $1.3 Million	476,251 Added 8.25%	6,245,990 $3.76 Million
Q4 2021 Feb 14, 2022	BUY	$2.33 - $3.37 $1.11 Million - $1.6 Million	475,261 Added 8.98%	5,769,739 $15.4 Million
Q3 2021 Nov 12, 2021	BUY	$2.52 - $2.99 $102,516 - $121,636	40,681 Added 0.77%	5,294,478 $14.6 Million
Q2 2021 Aug 13, 2021	BUY	$2.6 - $3.65 $13.7 Million - $19.2 Million	5,253,797 New	5,253,797 $15 Million

Ticker MEIP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 133,261,000
Market Cap $385M
Description
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymp...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.